MET

Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

Retrieved on: 
onsdag, maj 8, 2024
FDA, CFO, Research, CRC, Partnership, PDAC, ASCO, CD137, AACR, Biomarker, EGFR, Lung cancer, Non-small-cell lung cancer, Drug design, Illinois State University, HER2, Food, Bristol Myers Squibb, Patent, Eli Lilly and Company, BLA, NRG1, Therapy, NSCLC, PYC, Safety, Cetuximab, Pembrolizumab, Marketing, Clinical trial, CD3, MET, HNSCC, Gilead Sciences, Betta, Epitope, Biologics license application, Patient, Antigen, Head, Pharmaceutical industry

Merus plans to provide updated efficacy, durability and safety data of this cohort in the second half of 2024.

Key Points: 
  • Merus plans to provide updated efficacy, durability and safety data of this cohort in the second half of 2024.
  • In 2024, Merus is planning to initiate the evaluation of petosemtamab with standard chemotherapy in 2L CRC.
  • During the first quarter of 2024, Merus achieved a milestone of $1 million for candidate nomination and expects to receive payment in the second quarter of 2024.
  • In March 2024, Merus and Gilead Sciences announced a collaboration to discover novel antibody based trispecific T-cell engagers using Merus’ patented Triclonics® platform.

Global $46.7B Cancer Biomarkers Market Outlook, 2035: MET Biomarkers Lead the Charge, Driven by Rising Incidence of Lung Cancer and Drug Development - ResearchAndMarkets.com

Retrieved on: 
onsdag, maj 8, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Foundation Medicine, MSI, Lung cancer, Breast cancer, Blood, AI, MDPI, Skin cancer, Agilent Technologies, Prostate cancer, Biomarker, ALK, Kidney cancer, EGFR, OncoDNA, Cancer, Bladder cancer, Tempus, Son, Non-small-cell lung cancer, Frontiers Media, HER2, Colorectal cancer, Turbine, Thyroid cancer, ARUP Laboratories, Roche, Database, Therapy, Merck, NSCLC, Thermo Fisher Scientific, Nature, Publication, Laboratory, Survival, Insurance, BioMed Central, Nature Portfolio, Incidence, Drug development, Liver cancer, Liquid biopsy, MET, NTRK, CK Life Sciences, Endometrial cancer, Actuate, PD-L1, Patient, Gastrointestinal cancer, Physician, Neoplasm, Head, Medical imaging

Based on the type of cancer, the cancer biomarkers market is segmented into Breast Cancer, Prostate Cancer, Colorectum Cancer, Lung Cancer, Thyroid Cancer, Bladder Cancer, Melanoma, Non-Hodgkins Lymphoma, Endometrial Cancer, Kidney Cancer and Leukemia.

Key Points: 
  • Based on the type of cancer, the cancer biomarkers market is segmented into Breast Cancer, Prostate Cancer, Colorectum Cancer, Lung Cancer, Thyroid Cancer, Bladder Cancer, Melanoma, Non-Hodgkins Lymphoma, Endometrial Cancer, Kidney Cancer and Leukemia.
  • Currently, the market is driven by breast cancer biomarkers and lung cancer biomarkers; however, in the coming future, we anticipate cancer biomarker market for leukemia to grow at a significant pace.
  • The market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the companies involved in the cancer biomarkers market.
  • It is worth mentioning that Merck is conducting the maximum number of trials in this industry for various cancer indications, including bladder cancer, breast cancer, colorectal cancer, gastrointestinal cancer, gynecological cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer and skin cancer.

MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024

Retrieved on: 
tisdag, maj 7, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, EAP, Cancer, MET, Congress, Safety, Haematopoietic system, Survival, Institut Gustave Roussy, Maat, Partnership, Trial of the century, Artificial intelligence, AP-HP, DSMB, ICI, IGR, PICASSO, Rated R, Patient, ARES, Doctor of Pharmacy, D28, INRAE, Lung, EBMT, ALS, AACR, NSCLC, Lung cancer, Pharmaceutical industry

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today provided a business update and highlights its key milestones for 2024.

Key Points: 
  • MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today provided a business update and highlights its key milestones for 2024.
  • Hervé Affagard, CEO and co-founder of MaaT Pharma said: “We're confidently advancing towards Phase 3 results for MaaT013, meeting milestones and delivering value for shareholders.
  • This study was not requested by regulatory authorities and does not impact cash projections as funding has already been secured.
  • The related costs for MaaT Pharma are limited to clinical product supply in line with previous cash projections.

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Retrieved on: 
torsdag, april 25, 2024
Glioma, Shanda, MET, WHO, Temozolomide, Safety, Risk, NMPA, National Medical Products Administration, Glioblastoma, Isocitrate dehydrogenase, Survival, New Drug Application, Cisplatin, Death, Central nervous system, Partnership, Trial of the century, Etoposide, OS, History, CNS, IDH, Patient, Neoplasm, Met, APLM, NSCLC, Lung cancer, Pharmaceutical industry

FOSTER CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that its partner in China, Avistone Biotechnology Co. Ltd. (Avistone), received approval from the National Medical Products Administration (NMPA) of China for vebreltinib (APL-101) for the treatment of adult patients with isocitrate dehydrogenase (IDH) mutant astrocytoma (WHO Grade 4) or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion (ZM fusion) gene and have failed previous treatments. This supplemental New Drug Application (sNDA) approval makes vebreltinib the world’s first c-Met inhibitor approved for treatment of Central Nervous System (CNS) tumor with c-Met alteration, and follows the NMPA’s November 2023 approval of vebreltinib for the treatment of patients with Met Exon 14 skipping non-small cell lung cancer (NSCLC).

Key Points: 
  • "The NMPA’s approval of vebreltinib in gliomas is an important, first-in-class approval as it demonstrates vebreltinib’s CNS penetration ability and c-Met inhibitory activity in the tumors there," said Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics.
  • Surgery, radiation treatment, and chemotherapy are current standard treatment strategies for gliomas with poor prognoses.
  • These preliminary data support cross-region similarity of patient response to treatment with vebreltinib.
  • This collaboration enables both companies to leverage their strengths and maximize the benefit of vebreltinib worldwide.

COLLEGE FOR CREATIVE STUDIES STUDENTS RECREATE HISTORICAL GARMENTS FROM DETROIT INSTITUTE OF ARTS ARTWORKS

Retrieved on: 
torsdag, april 25, 2024
MET, Education, DIA, Collection, Student, Life, Metropolitan Museum of Art, CCS, Detroit Institute of Arts, College, Creativity, Fashion design

Students were tasked to explore the production of historical garment recreation, working with the Detroit Institute of Arts (DIA) to create historical garments inspired by works in the museum’s collection.

Key Points: 
  • Students were tasked to explore the production of historical garment recreation, working with the Detroit Institute of Arts (DIA) to create historical garments inspired by works in the museum’s collection.
  • CCS and the DIA have also partnered to create a short film showcasing the student’s completed pieces.
  • With the exception of works dependent on color to convey cultural significance, students designed these historical garments without using any colored or patterned materials.
  • “We are thrilled to see the creativity and virtuosity that the CCS fashion students have brought to the magnificent garments inspired by the museum’s collections.

MetLife CFO John McCallion Provides First Quarter 2024 Financial Update Video

Retrieved on: 
onsdag, maj 1, 2024
Finance, Banking, Professional Services, Asset Management, Insurance, Multimedia, Head, MET, McCallion, MetLife

MetLife, Inc. (NYSE: MET) today announced that John McCallion, executive vice president and chief financial officer, MetLife, Inc., and head of MetLife Investment Management, has provided a first quarter 2024 financial update video.

Key Points: 
  • MetLife, Inc. (NYSE: MET) today announced that John McCallion, executive vice president and chief financial officer, MetLife, Inc., and head of MetLife Investment Management, has provided a first quarter 2024 financial update video.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240501662440/en/

MetLife Announces New $3 Billion Share Repurchase Authorization

Retrieved on: 
onsdag, maj 1, 2024
Professional Services, Insurance, Finance, Asset Management, Consulting, Banking, Share repurchase, MET, Growth, MetLife

MetLife, Inc. (NYSE: MET) today announced that its board of directors has approved a new $3 billion authorization for the company to repurchase its common stock.

Key Points: 
  • MetLife, Inc. (NYSE: MET) today announced that its board of directors has approved a new $3 billion authorization for the company to repurchase its common stock.
  • The new authorization is incremental to the approximately $600 million remaining at the end of April 2024 under the company’s prior authorization announced in May 2023.
  • “This $3 billion addition to our share repurchase authorization, combined with the common stock dividend increase we announced in April, demonstrates our commitment to returning capital to shareholders, which is carefully balanced with investing in responsible growth for the future,” said MetLife President and CEO Michel Khalaf.
  • “Our disciplined approach directs capital to the highest value opportunities and drives long-term shareholder value.”

Data Presented at AACR 2024 Showcase Precede Biosciences’ Power to Impact Precision Medicine from a Simple Blood Test

Retrieved on: 
onsdag, april 10, 2024
MET, Hospital, HER2, HER3, Breast, MD, CEACAM5, Patient, CLDN18, Lung, Health, Biology, AACR, EGFR, Massachusetts General Hospital, Plasma, Pharmaceutical industry

Data further underscore potential to inform therapy selection for antibody drug conjugates and other target-directed therapies across breast, lung, and gastro-esophageal cancers

Key Points: 
  • Data further underscore potential to inform therapy selection for antibody drug conjugates and other target-directed therapies across breast, lung, and gastro-esophageal cancers
    Targets revealed from a single 1mL plasma sample include B7H4, CEACAM5, CLDN18, EGFR, HER2, HER3, MET, NECTIN4, and TROP2
    BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class comprehensive epigenomic liquid biopsy platform, today shared three scientific poster presentations from the 2024 American Association for Cancer Research (AACR) Annual Meeting.
  • “The data presented at AACR 2024 add to the growing body of evidence supporting our platform’s unique ability to provide genome-wide insight into the activation status of therapeutic targets, pathways, and resistance mechanisms, all from a simple blood draw,” said Carl Barrett, Chief Scientific Officer of Precede Bio.
  • “As such, we have a significant opportunity to better inform patient selection and enable indication expansion for the many promising agents addressing these targets and pathways with our platform.”
    “Our study highlights the need for new approaches to profile the biology of gastro-esophageal adenocarcinoma, an aggressive disease in which patients can progress quickly,” said Samuel Klempner, MD, medical oncologist at Massachusetts General Hospital and senior author for the abstract on gastro-esophageal cancers.
  • “Precede Bio’s liquid biopsy platform could represent an important advance enabling informed treatment decisions and personalized patient care throughout the cancer journey for this difficult-to-treat cancer.”
    Precede Bio’s posters from AACR 2024 can be found in the presentations section of the company website and are linked directly below:

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
onsdag, april 10, 2024
AACR, MET, EGFR, Cancer, Patient, Doctor of Philosophy, NSCLC, Hepatocyte growth factor, Medical imaging

FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, presented two posters at the 2024 American Association for Cancer Research (AACR) Annual Meeting, held April 5-10, 2024 in San Diego, Calif.

Key Points: 
  • FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, presented two posters at the 2024 American Association for Cancer Research (AACR) Annual Meeting, held April 5-10, 2024 in San Diego, Calif.
  • Copies of the posters are available on the Apollomics website at ir.apollomicsinc.com/news-events/presentations .
  • “Vebreltinib’s selectivity and high in vivo potency against multiple tumor types in a variety of patient-derived tumor models demonstrate its potential to treat a variety of MET-altered tumors, as a single agent or in combination,” said Guo-Liang Yu, PhD, Chairman and Chief Executive Officer of Apollomics.
  • The second poster presented, titled, “Dependence of EGFR-mutant NSCLC on MET as demonstrated by vebreltinib, a novel and selective brain-penetrating MET kinase inhibitor,” demonstrated that adding vebreltinib to EGFR therapies overcomes MET-amplification dependent resistance with durable effect or prevents MET-dependent resistance to maximize therapeutic benefits.

Avistone Announces the Approval of Vebreltinib as the First MET-TKI Treatment for a Rare Brain Glioma Subtype in China

Retrieved on: 
torsdag, april 25, 2024
Oncology, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Glioma, Shanda, MET, Temozolomide, Safety, Radiation, NMPA, Glioblastoma, Isocitrate dehydrogenase, Prognosis, Survival, New Drug Application, Cisplatin, Death, Central nervous system, Lung cancer, Etoposide, OS, History, Risk, CNS, Therapy, IDH, Patient, Neoplasm, NSCLC, Pharmaceutical industry

This supplemental New Drug Application (sNDA) approval makes vebreltinib the world’s first c-Met inhibitor approved for treatment of Central Nervous System (CNS) tumor with c-Met alteration.

Key Points: 
  • This supplemental New Drug Application (sNDA) approval makes vebreltinib the world’s first c-Met inhibitor approved for treatment of Central Nervous System (CNS) tumor with c-Met alteration.
  • In November 2023, vebreltinib received conditional approval for the treatment of metastatic patients with MET Exon14 Skipping non-small cell lung cancer (NSCLC) from the NMPA.
  • Glioma is a refractory primary malignant intracranial tumor, accounting for approximately 46% of intracranial tumors [1].
  • The approval of vebreltinib for the ZM fusion-positive glioma indications is based on the positive results of the FUGEN study (NCT06105619).